Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]
Clinical data | |
---|---|
Trade names | Celontin |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a682028 |
Routes of administration | By mouth (capsules) |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic (demethylation and glucuronidation) |
Metabolites | N-desmethylmethosuximide |
Elimination half-life | 1.4–2.6 hours (mesuximide) 28–38 hours (active metabolite) |
Excretion | Urine |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.000.934 |
Chemical and physical data | |
Formula | C12H13NO2 |
Molar mass | 203.241 g·mol−1 |
3D model (JSmol) |
|
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
is indicated for the control of absence seizures that are refractory to other drugs.[2]